EXOZeXoZymes Inc. Common Stock
7.150USD+11.72%Mkt Cap: 66.36M $P/E: —3d ago
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
| Headline | Source | Time |
|---|---|---|
Older | ||
 eXoZymes Q2 Earnings Call Highlights eXoZymes (NASDAQ:EXOZ) outlined progress toward commercializing its NCT program, including a reported tenfold increase in process productivity versus its March pilot campaign, while management said it expects to select a manufacturing partner by the end of the third quarter and identify a market lau | ||
MDB Capital Holdings LLC (MDBH) (Q2 2026) Earnings Call Highlights: Strategic Pivots and Asset ... CEO Christopher Marlett outlines a leaner operational model, potential partnerships for Public Ventures, and a PatentVest spin-out as key catalysts to unlock shareholder value. | ||